ID   MAPK3_HUMAN             Reviewed;         382 AA.
AC   Q16644; B5BU67;
DT   06-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   15-MAR-2017, entry version 154.
DE   RecName: Full=MAP kinase-activated protein kinase 3;
DE            Short=MAPK-activated protein kinase 3;
DE            Short=MAPKAP kinase 3;
DE            Short=MAPKAP-K3;
DE            Short=MAPKAPK-3;
DE            Short=MK-3;
DE            EC=2.7.11.1;
DE   AltName: Full=Chromosome 3p kinase;
DE            Short=3pK;
GN   Name=MAPKAPK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=8626550; DOI=10.1074/jbc.271.14.8488;
RA   McLaughlin M.M., Kumar S., McDonnell P.C., Van Horn S., Lee J.C.,
RA   Livi G.P., Young P.R.;
RT   "Identification of mitogen-activated protein (MAP) kinase-activated
RT   protein kinase-3, a novel substrate of CSBP p38 MAP kinase.";
RL   J. Biol. Chem. 271:8488-8492(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND PHOSPHORYLATION BY
RP   MAPK1/ERK2 AND MAPK3/ERK1.
RC   TISSUE=Heart;
RX   PubMed=8622688; DOI=10.1128/MCB.16.3.868;
RA   Sithanandam G., Latif F., Duh F.-M., Bernal R., Smola U., Li H.,
RA   Kuzmin I., Wixler V., Geil L., Shrestha S., Lloyd P.A., Bader S.,
RA   Sekido Y., Tartof K.D., Kashuba V.I., Zabarovsky E.R., Dean M.,
RA   Klein G., Lerman M.I., Minna J.D., Rapp U.R., Allikmets R.;
RT   "3pK, a new mitogen-activated protein kinase-activated protein kinase
RT   located in the small cell lung cancer tumor suppressor gene region.";
RL   Mol. Cell. Biol. 16:868-876(1996).
RN   [3]
RP   ERRATUM.
RA   Sithanandam G., Latif F., Duh F.-M., Bernal R., Smola U., Li H.,
RA   Kuzmin I., Wixler V., Geil L., Shrestha S., Lloyd P.A., Bader S.,
RA   Sekido Y., Tartof K.D., Kashuba V.I., Zabarovsky E.R., Dean M.,
RA   Klein G., Lerman M.I., Minna J.D., Rapp U.R., Allikmets R.;
RL   Mol. Cell. Biol. 16:1880-1880(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, AND FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=8774846; DOI=10.1016/0014-5793(96)00816-2;
RA   Clifton A.D., Young P.R., Cohen P.;
RT   "A comparison of the substrate specificity of MAPKAP kinase-2 and
RT   MAPKAP kinase-3 and their activation by cytokines and cellular
RT   stress.";
RL   FEBS Lett. 392:209-214(1996).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=10383393; DOI=10.1074/jbc.274.27.18947;
RA   Rogalla T., Ehrnsperger M., Preville X., Kotlyarov A., Lutsch G.,
RA   Ducasse C., Paul C., Wieske M., Arrigo A.P., Buchner J., Gaestel M.;
RT   "Regulation of Hsp27 oligomerization, chaperone function, and
RT   protective activity against oxidative stress/tumor necrosis factor
RT   alpha by phosphorylation.";
RL   J. Biol. Chem. 274:18947-18956(1999).
RN   [9]
RP   INTERACTION WITH TCF3.
RX   PubMed=10781029; DOI=10.1074/jbc.C901040199;
RA   Neufeld B., Grosse-Wilde A., Hoffmeyer A., Jordan B.W., Chen P.,
RA   Dinev D., Ludwig S., Rapp U.R.;
RT   "Serine/Threonine kinases 3pK and MAPK-activated protein kinase 2
RT   interact with the basic helix-loop-helix transcription factor E47 and
RT   repress its transcriptional activity.";
RL   J. Biol. Chem. 275:20239-20242(2000).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15302577; DOI=10.1016/j.yexcr.2004.05.027;
RA   Zakowski V., Keramas G., Kilian K., Rapp U.R., Ludwig S.;
RT   "Mitogen-activated 3p kinase is active in the nucleus.";
RL   Exp. Cell Res. 299:101-109(2004).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF LYS-73, AND INTERACTION WITH PHC2 AND BMI1.
RX   PubMed=15563468; DOI=10.1074/jbc.M407155200;
RA   Voncken J.W., Niessen H., Neufeld B., Rennefahrt U., Dahlmans V.,
RA   Kubben N., Holzer B., Ludwig S., Rapp U.R.;
RT   "MAPKAP kinase 3pK phosphorylates and regulates chromatin association
RT   of the polycomb group protein Bmi1.";
RL   J. Biol. Chem. 280:5178-5187(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF TAB3.
RX   PubMed=18021073; DOI=10.1042/BJ20071149;
RA   Mendoza H., Campbell D.G., Burness K., Hastie J., Ronkina N.,
RA   Shim J.H., Arthur J.S., Davis R.J., Gaestel M., Johnson G.L.,
RA   Ghosh S., Cohen P.;
RT   "Roles for TAB1 in regulating the IL-1-dependent phosphorylation of
RT   the TAB3 regulatory subunit and activity of the TAK1 complex.";
RL   Biochem. J. 409:711-722(2008).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   FUNCTION.
RX   PubMed=20599781; DOI=10.1016/j.bcp.2010.06.021;
RA   Ronkina N., Menon M.B., Schwermann J., Tiedje C., Hitti E.,
RA   Kotlyarov A., Gaestel M.;
RT   "MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF
RT   biosynthesis via expression and phosphorylation of tristetraprolin.";
RL   Biochem. Pharmacol. 80:1915-1920(2010).
RN   [15]
RP   REVIEW.
RX   PubMed=18508601; DOI=10.2741/3095;
RA   Ronkina N., Kotlyarov A., Gaestel M.;
RT   "MK2 and MK3--a pair of isoenzymes?";
RL   Front. Biosci. 13:5511-5521(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INVOLVEMENT IN MDPT3,
RP   VARIANT MDPT3 PRO-173, AND CHARACTERIZATION OF VARIANT MDPT3 PRO-173.
RX   PubMed=26744326; DOI=10.1093/hmg/ddv624;
RA   Meunier I., Lenaers G., Bocquet B., Baudoin C., Piro-Megy C.,
RA   Cubizolle A., Quiles M., Jean-Charles A., Cohen S.Y., Merle H.,
RA   Gaudric A., Labesse G., Manes G., Pequignot M., Cazevieille C.,
RA   Dhaenens C.M., Fichard A., Ronkina N., Arthur S.J., Gaestel M.,
RA   Hamel C.P.;
RT   "A dominant mutation in MAPKAPK3, an actor of p38 signaling pathway,
RT   causes a new retinal dystrophy involving Bruch's membrane and retinal
RT   pigment epithelium.";
RL   Hum. Mol. Genet. 25:916-926(2016).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 33-349 IN COMPLEX WITH
RP   INHIBITOR P4O.
RX   PubMed=19937655; DOI=10.1002/pro.294;
RA   Cheng R., Felicetti B., Palan S., Toogood-Johnson I., Scheich C.,
RA   Barker J., Whittaker M., Hesterkamp T.;
RT   "High-resolution crystal structure of human Mapkap kinase 3 in complex
RT   with a high affinity ligand.";
RL   Protein Sci. 19:168-173(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS) OF 33-349 IN COMPLEX WITH
RP   INHIBITOR 5B.
RX   PubMed=21565500; DOI=10.1016/j.bmcl.2011.04.018;
RA   Barf T., Kaptein A., de Wilde S., van der Heijden R., van Someren R.,
RA   Demont D., Schultz-Fademrecht C., Versteegh J., van Zeeland M.,
RA   Seegers N., Kazemier B., van de Kar B., van Hoek M., de Roos J.,
RA   Klop H., Smeets R., Hofstra C., Hornberg J., Oubrie A.;
RT   "Structure-based lead identification of ATP-competitive MK2
RT   inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:3818-3822(2011).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-28; ALA-105 AND TYR-276.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Stress-activated serine/threonine-protein kinase
CC       involved in cytokines production, endocytosis, cell migration,
CC       chromatin remodeling and transcriptional regulation. Following
CC       stress, it is phosphorylated and activated by MAP kinase p38-
CC       alpha/MAPK14, leading to phosphorylation of substrates.
CC       Phosphorylates serine in the peptide sequence, Hyd-X-R-X(2)-S,
CC       where Hyd is a large hydrophobic residue. MAPKAPK2 and MAPKAPK3,
CC       share the same function and substrate specificity, but MAPKAPK3
CC       kinase activity and level in protein expression are lower compared
CC       to MAPKAPK2. Phosphorylates HSP27/HSPB1, KRT18, KRT20, RCSD1,
CC       RPS6KA3, TAB3 and TTP/ZFP36. Mediates phosphorylation of
CC       HSP27/HSPB1 in response to stress, leading to dissociate
CC       HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers
CC       and impair their chaperone activities and ability to protect
CC       against oxidative stress effectively. Involved in inflammatory
CC       response by regulating tumor necrosis factor (TNF) and IL6
CC       production post-transcriptionally: acts by phosphorylating AU-rich
CC       elements (AREs)-binding proteins, such as TTP/ZFP36, leading to
CC       regulate the stability and translation of TNF and IL6 mRNAs.
CC       Phosphorylation of TTP/ZFP36, a major post-transcriptional
CC       regulator of TNF, promotes its binding to 14-3-3 proteins and
CC       reduces its ARE mRNA affinity leading to inhibition of dependent
CC       degradation of ARE-containing transcript. Involved in toll-like
CC       receptor signaling pathway (TLR) in dendritic cells: required for
CC       acute TLR-induced macropinocytosis by phosphorylating and
CC       activating RPS6KA3. Also acts as a modulator of Polycomb-mediated
CC       repression. {ECO:0000269|PubMed:10383393,
CC       ECO:0000269|PubMed:15563468, ECO:0000269|PubMed:18021073,
CC       ECO:0000269|PubMed:20599781, ECO:0000269|PubMed:8626550,
CC       ECO:0000269|PubMed:8774846}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:8774846}.
CC   -!- ENZYME REGULATION: Activated following phosphorylation by p38-
CC       alpha/MAPK14 following various stresses. Inhibited by ligand 5B
CC       (2'-[2-(1,3-benzodioxol-5-yl)pyrimidin-4-yl]-5',6'-
CC       dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]- 4'(1'h)-one)
CC       and ligand P4O (2-[2-(2-fluorophenyl)pyridin-4-yl]-1,5,6,7-
CC       tetrahydro- 4h-pyrrolo[3,2-c]pyridin-4-one), 2 ATP-competitive
CC       inhibitors.
CC   -!- SUBUNIT: Heterodimer with p38-alpha/MAPK14. The heterodimer with
CC       p38-alpha/MAPK14 forms a stable complex: molecules are positioned
CC       'face to face' so that the ATP-binding sites of both kinases are
CC       at the heterodimer interface (By similarity). Interacts with TCF3
CC       and with polycomb proteins, such as PCH2 and BMI1/PCGF4.
CC       {ECO:0000250, ECO:0000269|PubMed:10781029,
CC       ECO:0000269|PubMed:15563468, ECO:0000269|PubMed:19937655,
CC       ECO:0000269|PubMed:21565500}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=5; IntAct=EBI-1384657, EBI-6377335;
CC       P04792:HSPB1; NbExp=3; IntAct=EBI-1384657, EBI-352682;
CC       Q16539:MAPK14; NbExp=5; IntAct=EBI-1384657, EBI-73946;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15302577,
CC       ECO:0000269|PubMed:26744326}. Cytoplasm
CC       {ECO:0000269|PubMed:15302577, ECO:0000269|PubMed:26744326}.
CC       Note=Predominantly located in the nucleus, when activated it
CC       translocates to the cytoplasm.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with a higher expression
CC       level observed in heart and skeletal muscle. No expression in
CC       brain. Expressed in the retinal pigment epithelium
CC       (PubMed:26744326). {ECO:0000269|PubMed:26744326,
CC       ECO:0000269|PubMed:8622688, ECO:0000269|PubMed:8626550}.
CC   -!- PTM: Phosphorylated and activated by MAPK1/ERK2 and MAPK3/ERK1.
CC       Phosphorylated and activated by MAP kinase p38-alpha/MAPK14 at
CC       Thr-201, Ser-251 and Thr-313 (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Macular dystrophy, patterned, 3 (MDPT3) [MIM:617111]: A
CC       form of retinal patterned dystrophy, characterized by retinal
CC       pigment epithelium and Bruch's membrane changes resembling a 'dry
CC       desert land'. It begins around the age of 30 and progresses to
CC       retinitis pigmentosa. MDPT3 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:26744326}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U43784; AAC50428.1; -; mRNA.
DR   EMBL; U09578; AAD09136.1; -; mRNA.
DR   EMBL; AB451303; BAG70117.1; -; mRNA.
DR   EMBL; CH471055; EAW65131.1; -; Genomic_DNA.
DR   EMBL; BC001662; AAH01662.1; -; mRNA.
DR   EMBL; BC007591; AAH07591.1; -; mRNA.
DR   EMBL; BC010407; AAH10407.1; -; mRNA.
DR   CCDS; CCDS2832.1; -.
DR   PIR; JC6094; JC6094.
DR   RefSeq; NP_001230854.1; NM_001243925.1.
DR   RefSeq; NP_001230855.1; NM_001243926.1.
DR   RefSeq; NP_004626.1; NM_004635.4.
DR   UniGene; Hs.234521; -.
DR   UniGene; Hs.735013; -.
DR   PDB; 3FHR; X-ray; 1.90 A; A=33-349.
DR   PDB; 3FXW; X-ray; 2.00 A; A=33-349.
DR   PDB; 3R1N; X-ray; 2.09 A; A=33-349.
DR   PDB; 3SHE; X-ray; 2.25 A; A=33-349.
DR   PDBsum; 3FHR; -.
DR   PDBsum; 3FXW; -.
DR   PDBsum; 3R1N; -.
DR   PDBsum; 3SHE; -.
DR   ProteinModelPortal; Q16644; -.
DR   SMR; Q16644; -.
DR   BioGrid; 113617; 24.
DR   IntAct; Q16644; 27.
DR   MINT; MINT-3032958; -.
DR   STRING; 9606.ENSP00000350639; -.
DR   BindingDB; Q16644; -.
DR   ChEMBL; CHEMBL4670; -.
DR   GuidetoPHARMACOLOGY; 2095; -.
DR   iPTMnet; Q16644; -.
DR   PhosphoSitePlus; Q16644; -.
DR   BioMuta; MAPKAPK3; -.
DR   DMDM; 74762148; -.
DR   EPD; Q16644; -.
DR   MaxQB; Q16644; -.
DR   PaxDb; Q16644; -.
DR   PeptideAtlas; Q16644; -.
DR   PRIDE; Q16644; -.
DR   DNASU; 7867; -.
DR   Ensembl; ENST00000357955; ENSP00000350639; ENSG00000114738.
DR   Ensembl; ENST00000446044; ENSP00000396467; ENSG00000114738.
DR   Ensembl; ENST00000621469; ENSP00000478922; ENSG00000114738.
DR   GeneID; 7867; -.
DR   KEGG; hsa:7867; -.
DR   UCSC; uc003day.3; human.
DR   CTD; 7867; -.
DR   DisGeNET; 7867; -.
DR   GeneCards; MAPKAPK3; -.
DR   HGNC; HGNC:6888; MAPKAPK3.
DR   HPA; HPA058275; -.
DR   MIM; 602130; gene.
DR   MIM; 617111; phenotype.
DR   neXtProt; NX_Q16644; -.
DR   OpenTargets; ENSG00000114738; -.
DR   PharmGKB; PA30632; -.
DR   eggNOG; KOG0604; Eukaryota.
DR   eggNOG; ENOG410XP8F; LUCA.
DR   GeneTree; ENSGT00830000128274; -.
DR   HOGENOM; HOG000233031; -.
DR   HOVERGEN; HBG106948; -.
DR   InParanoid; Q16644; -.
DR   KO; K04444; -.
DR   OMA; SGCRHIV; -.
DR   OrthoDB; EOG091G14PL; -.
DR   PhylomeDB; Q16644; -.
DR   TreeFam; TF312891; -.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   SignaLink; Q16644; -.
DR   SIGNOR; Q16644; -.
DR   ChiTaRS; MAPKAPK3; human.
DR   EvolutionaryTrace; Q16644; -.
DR   GeneWiki; MAPKAPK3; -.
DR   GenomeRNAi; 7867; -.
DR   PRO; PR:Q16644; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114738; -.
DR   CleanEx; HS_MAPKAPK3; -.
DR   ExpressionAtlas; Q16644; baseline and differential.
DR   Genevisible; Q16644; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0044351; P:macropinocytosis; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0034097; P:response to cytokine; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0006950; P:response to stress; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 4.10.1170.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027442; MAPKAPK_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Disease mutation; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    382       MAP kinase-activated protein kinase 3.
FT                                /FTId=PRO_0000086293.
FT   DOMAIN       44    304       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      50     58       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      307    343       Autoinhibitory helix. {ECO:0000250}.
FT   REGION      345    369       p38 MAPK-binding site. {ECO:0000250}.
FT   MOTIF       335    344       Nuclear export signal (NES).
FT                                {ECO:0000250}.
FT   MOTIF       350    353       Bipartite nuclear localization signal 1.
FT                                {ECO:0000250}.
FT   MOTIF       364    368       Bipartite nuclear localization signal 2.
FT                                {ECO:0000250}.
FT   ACT_SITE    166    166       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      73     73       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     201    201       Phosphothreonine; by MAPK14.
FT                                {ECO:0000250}.
FT   MOD_RES     251    251       Phosphoserine; by MAPK14. {ECO:0000250}.
FT   MOD_RES     307    307       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     313    313       Phosphothreonine; by MAPK14.
FT                                {ECO:0000250}.
FT   VARIANT      28     28       P -> S (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040755.
FT   VARIANT     105    105       E -> A (in an ovarian endometrioid
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040756.
FT   VARIANT     173    173       L -> P (in MDPT3; decreased localization
FT                                to the nucleus).
FT                                {ECO:0000269|PubMed:26744326}.
FT                                /FTId=VAR_077085.
FT   VARIANT     276    276       D -> Y (in dbSNP:rs56107897).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040757.
FT   MUTAGEN      73     73       K->M: Higher affinity toward PCH2.
FT                                {ECO:0000269|PubMed:15563468}.
FT   HELIX        39     41       {ECO:0000244|PDB:3FHR}.
FT   STRAND       43     53       {ECO:0000244|PDB:3FHR}.
FT   STRAND       56     63       {ECO:0000244|PDB:3FHR}.
FT   TURN         64     66       {ECO:0000244|PDB:3FHR}.
FT   STRAND       69     78       {ECO:0000244|PDB:3FHR}.
FT   HELIX        79     91       {ECO:0000244|PDB:3FHR}.
FT   STRAND      100    108       {ECO:0000244|PDB:3FHR}.
FT   STRAND      111    119       {ECO:0000244|PDB:3FHR}.
FT   HELIX       126    131       {ECO:0000244|PDB:3FHR}.
FT   HELIX       140    159       {ECO:0000244|PDB:3FHR}.
FT   HELIX       169    171       {ECO:0000244|PDB:3FHR}.
FT   STRAND      172    175       {ECO:0000244|PDB:3FHR}.
FT   STRAND      183    185       {ECO:0000244|PDB:3FHR}.
FT   HELIX       218    237       {ECO:0000244|PDB:3FHR}.
FT   TURN        267    269       {ECO:0000244|PDB:3FHR}.
FT   STRAND      271    273       {ECO:0000244|PDB:3R1N}.
FT   HELIX       275    284       {ECO:0000244|PDB:3FHR}.
FT   HELIX       289    291       {ECO:0000244|PDB:3FHR}.
FT   HELIX       295    300       {ECO:0000244|PDB:3FHR}.
FT   HELIX       302    305       {ECO:0000244|PDB:3FHR}.
FT   HELIX       307    309       {ECO:0000244|PDB:3FHR}.
FT   HELIX       317    323       {ECO:0000244|PDB:3FHR}.
FT   HELIX       325    327       {ECO:0000244|PDB:3FHR}.
FT   HELIX       328    343       {ECO:0000244|PDB:3FHR}.
FT   STRAND      344    346       {ECO:0000244|PDB:3SHE}.
SQ   SEQUENCE   382 AA;  42987 MW;  405F958B7F54E6F3 CRC64;
     MDGETAEEQG GPVPPPVAPG GPGLGGAPGG RREPKKYAVT DDYQLSKQVL GLGVNGKVLE
     CFHRRTGQKC ALKLLYDSPK ARQEVDHHWQ ASGGPHIVCI LDVYENMHHG KRCLLIIMEC
     MEGGELFSRI QERGDQAFTE REAAEIMRDI GTAIQFLHSH NIAHRDVKPE NLLYTSKEKD
     AVLKLTDFGF AKETTQNALQ TPCYTPYYVA PEVLGPEKYD KSCDMWSLGV IMYILLCGFP
     PFYSNTGQAI SPGMKRRIRL GQYGFPNPEW SEVSEDAKQL IRLLLKTDPT ERLTITQFMN
     HPWINQSMVV PQTPLHTARV LQEDKDHWDE VKEEMTSALA TMRVDYDQVK IKDLKTSNNR
     LLNKRRKKQA GSSSASQGCN NQ
//
